purine has been researched along with Recrudescence in 5 studies
1H-purine : The 1H-tautomer of purine.
3H-purine : The 3H-tautomer of purine.
9H-purine : The 9H-tautomer of purine.
7H-purine : The 7H-tautomer of purine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 8.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
| "Frontline treatment of hairy cell leukemia (HCL) with a single course of the purine nucleoside analog (PNA) produces a high rate of complete remission (CR) with prolonged durations." | 4.12 | Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. ( Brander, D; Gonter-Aubin, K; Hanlon, A; Hill, BT; Hu, R; Kabel, C; Khajavian, S; Madanat, Y; Mato, A; Mian, A; Park, JH; Pinilla-Ibarz, J; Shadman, M; Stephens, DM; Tallman, M; Wei, W, 2022) |
| "Although hairy cell leukemia (HCL) was identified in 1958 by Bouroncle and colleagues, HCL remains in 2015 a mysterious disease." | 2.52 | New insights in the management of patients with hairy cell leukemia. ( Cornet, E; Damaj, G; Troussard, X, 2015) |
| "Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL)." | 1.42 | Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. ( Bai, Y; Chen, H; Chen, J; Chen, S; Chen, Y; Ding, J; Ding, L; Du, A; Ferrando, A; Gu, L; Huang, X; Jin, L; Kang, H; Kirschner-Schwabe, R; Li, B; Li, H; Li, W; Liang, H; Lu, G; Lu, H; Ma, X; Shen, S; Tang, J; Tzoneva, G; von Stackelberg, A; Wang, S; Wu, T; Yang, JJ; Yang, M; Zhang, J; Zhou, BB, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, R | 1 |
| Wei, W | 1 |
| Mian, A | 1 |
| Gonter-Aubin, K | 1 |
| Kabel, C | 1 |
| Mato, A | 1 |
| Stephens, DM | 1 |
| Hanlon, A | 1 |
| Khajavian, S | 1 |
| Shadman, M | 1 |
| Brander, D | 1 |
| Madanat, Y | 1 |
| Park, JH | 1 |
| Tallman, M | 1 |
| Pinilla-Ibarz, J | 1 |
| Hill, BT | 1 |
| Tzoneva, G | 2 |
| Dieck, CL | 1 |
| Oshima, K | 1 |
| Ambesi-Impiombato, A | 1 |
| Sánchez-Martín, M | 1 |
| Madubata, CJ | 1 |
| Khiabanian, H | 1 |
| Yu, J | 1 |
| Waanders, E | 1 |
| Iacobucci, I | 1 |
| Sulis, ML | 1 |
| Kato, M | 1 |
| Koh, K | 1 |
| Paganin, M | 1 |
| Basso, G | 1 |
| Gastier-Foster, JM | 1 |
| Loh, ML | 1 |
| Kirschner-Schwabe, R | 2 |
| Mullighan, CG | 1 |
| Rabadan, R | 1 |
| Ferrando, AA | 1 |
| Topp, ZZ | 1 |
| Saven, A | 1 |
| Li, B | 1 |
| Li, H | 1 |
| Bai, Y | 1 |
| Yang, JJ | 1 |
| Chen, Y | 1 |
| Lu, G | 1 |
| Ma, X | 1 |
| Wu, T | 1 |
| Li, W | 1 |
| Lu, H | 1 |
| Ding, L | 1 |
| Liang, H | 1 |
| Huang, X | 1 |
| Yang, M | 1 |
| Jin, L | 1 |
| Kang, H | 1 |
| Chen, S | 1 |
| Du, A | 1 |
| Shen, S | 1 |
| Ding, J | 1 |
| Chen, H | 1 |
| Chen, J | 1 |
| von Stackelberg, A | 1 |
| Gu, L | 1 |
| Zhang, J | 1 |
| Ferrando, A | 1 |
| Tang, J | 1 |
| Wang, S | 1 |
| Zhou, BB | 1 |
| Cornet, E | 1 |
| Damaj, G | 1 |
| Troussard, X | 1 |
2 reviews available for purine and Recrudescence
| Article | Year |
|---|---|
Hairy cell leukemia: a 'hair-raising' update.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow; Drug Therapy, Combination; Humans; Leuke | 2014 |
New insights in the management of patients with hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B-Lymphocytes; Disease-Free Survival; Humans; Immunot | 2015 |
3 other studies available for purine and Recrudescence
| Article | Year |
|---|---|
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Topics: Humans; Leukemia, Hairy Cell; Nucleosides; Purine Nucleosides; Purines; Recurrence; Rituximab; Treat | 2022 |
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Topics: 5'-Nucleotidase; Animals; Cell Proliferation; Clonal Evolution; Disease Models, Animal; Drug Resista | 2018 |
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
Topics: Adolescent; Child; Child, Preschool; Exome; Feedback, Physiological; Female; High-Throughput Nucleot | 2015 |